Thu. 21 Mar 2024, 6:02am ET
Benzinga
Earnings, News
Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.02) by 400 percent. This is a 61.54 percent increase over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $9.73 million which beat the analyst consensus estimate of $8.67 million by 12.28 percent. This is a 534.20 percent increase over sales of $1.53 million the same period last year.